Golfyeti,

I don't see how this gene therapy from Spark has anything to do with pricing of apabetalone. Spark's therapy woud be a one-time "procedure for a small group of under 2,000 potential patients, with fewer than 20 new patients per year" according to this EndPoints News article.  Very few patients have this RPE65 gene mutation for which this gene therapy corrects. It's a totally different ballgame for renal and cardiovascular diseases, which affect millions of patients who need to take one or more drugs regularly for possibly the rest of their lives. As opposed to a one-time (hopefully) gene therapy procedure from Spark, apabetalone would be administered daily over a long period of time. I don't see any similarities between pricing for Spark and pricing for apabetalone.

BearDownAZ